Hospital Universitari Vall d'Hebron - Oncology Dept.

Barcelona 08035

0 studies enrolling now · 7 studies all time

What they study most

Advanced Solid Tumor, Gastric Cancer, Head and Neck Cancer, Metastatic or Locally Advanced Unresectable Solid Tumors, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Solid Tumors

Studies at this site

• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Running, not enrolling
• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) — Running, not enrolling
• Avelumab Program Rollover Study — Running, not enrolling
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Running, not enrolling
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) — Running, not enrolling
• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) — Running, not enrolling
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early